Tesaro's rolapitant, its experimental drug for the prevention of chemotherapy-induced nausea and vomiting, achieved the primary goal of a Phase III trial by showing statistical significance compared with standard treatment in 532 cancer patients. The drug also demonstrated its efficacy in preventing CINV in two other late-stage studies. Tesaro said it was preparing to submit the drug for FDA review by the middle of this year.

Full Story:

Related Summaries